NOTE 3 – COMMITMENTS AND CONTINGENCIES:

Haisco Pharmaceuticals License Agreement

On June 22, 2026 (the "Execution Date"), the Company entered into an Exclusive License Agreement (the "Haisco Agreement") with Haisco Pharmaceutical Group Co., Ltd. ("Haisco"), pursuant to which Haisco granted the Company an exclusive, worldwide license (excluding Greater China, and, with respect to one of the two licensed compounds, also excluding India and certain Southeast Asian territories) to develop, manufacture, and commercialize two clinical-stage drug candidates: NXP100 (HSK39297, a Factor B inhibitor), and NXP200 (HSK42360, paradox breaker BRAF inhibitor).

​

The Haisco Agreement was subject to a financing condition, and it became effective on July 1, 2026, when the Company completed its public offering, thereby satisfying the financing condition. In addition, under the terms of the Haisco Agreement, in July 2026, subsequent to the closing of the public offering, the Company paid Haisco a one-time, non-refundable, non-creditable upfront payment of $20.0 million.

​

CRT Pioneer Fund License Agreement

There have been no material changes to the CRT Pioneer Fund License Agreement, as previously disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on February 11, 2026 (see Note 5a in the Notes to the Financial Statements in our Annual Report).

Any potential milestone or royalty payment amounts have not been accrued as of June 30, 2026, and December 31, 2025, due to the uncertainty related to the achievement of these events or milestones.  

University of Edinburgh License Agreement

There have been no material changes to the University of Edinburgh (“UoE”) License Agreement as previously disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on February 11, 2026 (see Note 5a in the Notes to the Financial Statements in our Annual Report).  

As of June 30, 2026, the Company has paid UoE $1.2 million of the total of up to $3.0 million related to the fundraising commitment.

There have been no related party transactions in the reported quarter.

As of June 30, 2026, and December 31, 2025, there are no contingent liabilities; therefore, no provision was made.